Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. - Wikidata - awgldk - TriplyDB

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.

http://www.wikidata.org/entity/Q38743794

about

Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations.PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.New insights into the role of EMT in tumor immune escape.Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression Escape from IFN-γ-dependent immunosurveillance in tumorigenesis.Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.ROS mediates interferon gamma induced phosphorylation of Src, through the Raf/ERK pathway, in MCF-7 human breast cancer cell line The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors.Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook.Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.Next-Generation Sequencing to Guide Treatment of Advanced Melanoma.The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors.Combination of IAP antagonist and IFNγ activates novel caspase-10- and RIPK1-dependent cell death pathways.Epigenetic regulation of immune checkpoints: another target for cancer immunotherapy?Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics.Applications of Immunogenomics to Cancer.Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.Cytokine-induced senescence for cancer surveillance.Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma.Interaction of molecular alterations with immune response in melanoma.Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer.Single-cell profiling of dynamic cytokine secretion and the phenotype of immune cells.DOCK8 Drives Src-Dependent NK Cell Effector Function.Role of Type I and II Interferons in Colorectal Cancer and Melanoma.HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes Checkpoint inhibitors in melanoma and early phase development in solid tumors: what's the future?Resistance to checkpoint blockade therapy through inactivation of antigen presentation.Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM).Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming.From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.Long non-coding RNA00364 represses hepatocellular carcinoma cell proliferation via modulating p-STAT3-IFIT2 signaling axis.Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade.Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.Informatics for cancer immunotherapy.Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.

P2860

Q33766695-2501C735-69EB-474E-BDDE-535CF8D19DE0 Q33779875-3F6BB60F-8850-4FAA-A75F-FFCB0239DB4E Q33839204-78B5C3A5-737F-4E50-93F4-9D8031CA9624 Q33869781-0706B76C-7F1D-4F4F-AD49-9E2B569A0D3A Q34550649-C741FBEA-2B34-46A0-9018-5CEE9E4673B9 Q37581437-9C2E9CEA-035C-441B-B08A-CDDC8DDE2744 Q37618482-9C345C2F-5207-4265-BB78-6321867F1EDB Q37713503-86CCA4E3-4064-431C-919F-02D1F25FA9CA Q37716710-F04E959C-5A76-47F8-A157-20FAD50B2A49 Q38401891-6408AAEE-F102-4868-B935-BAE43B3252D2 Q38657566-9B7B3FFF-1918-4CC5-97B8-C8C239507701 Q38677432-EC63D8F9-CCAC-4404-8420-90EDAE32B126 Q38727885-92C452AC-5883-446A-8EA2-3CA9505F860C Q38754313-3B64BEDC-6F48-47AD-8528-FA2DE6A86E6A Q38930244-5DD19EB8-61E0-48C3-BF33-C2A6ABCB7543 Q39010178-3E15D685-4FB6-497C-835E-EC56CA76E997 Q39045550-6D38A73A-F154-4178-81FE-7896D57F101A Q39108144-6D8037A2-59DF-4C49-9818-9AD657FF09D6 Q39130420-6948B75D-DD55-4A55-87E3-586669F27E22 Q39130451-65C943FC-2EF7-44A6-9387-D843A44D6896 Q39229370-86E59D47-593B-4E53-A272-D3B35FE6D6AB Q39312652-530D0C89-A8CA-4A77-A31E-B6EEAE4F78E1 Q39321608-45CA57CD-F0DE-42A7-8EE8-DF1EC5AD8FD1 Q39329609-E1EB7D09-0B64-4D48-B3EF-8050EBFCFEA6 Q39438805-EC4C2F74-34D2-4229-96EA-F2DC421C22C2 Q40081116-14FDE72D-0CC8-4C0F-811A-A6EB300A1300 Q40099675-DF45FB09-D422-4461-8413-E265B967027A Q41123286-139C45D8-F9D6-4104-8467-EC5DD72965A7 Q41633092-A32D3F84-22AF-4824-B082-A8705C18FDAC Q42343743-641548A0-4492-41CA-8733-039377F6C237 Q42630391-55A2B53B-7B54-414C-9F93-5F85688E4CC0 Q45822425-653198D9-AAAE-4FEE-961A-D09E7D60A104 Q45866445-F05EAE0E-7CBF-4BCB-B3C5-0EADF5349CD2 Q45952214-E8CA192F-4C53-4696-994A-458B1401608E Q46555595-154252B9-DD87-4E2F-AF99-69407B1F55D6 Q47122632-2BE102D4-BF9F-4999-A0C2-6AC6F03E991C Q47135020-198072AB-3038-4D70-BE04-BEF5E365309A Q47157659-30399BF5-B99B-4C0F-BE2B-EA951CC7E5AB Q47290509-BE0A9512-1D80-4BBE-9576-F920EA977FD1 Q47292249-3CF2538E-CB1D-47D3-A42C-A5A03B2DD35E

P2860

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.

http://www.wikidata.org/entity/Q38743794

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Loss of IFN-γ Pathway Genes in ...... stance to Anti-CTLA-4 Therapy.

@en

type

label

Loss of IFN-γ Pathway Genes in ...... stance to Anti-CTLA-4 Therapy.

@en

prefLabel

Loss of IFN-γ Pathway Genes in ...... stance to Anti-CTLA-4 Therapy.

@en

P1433

Q38743794-B8599233-083C-47D0-B50E-9F87B692C0AE

P1476

Q38743794-1A9F19B0-1354-4EB6-A4D6-FD14C782781E

P2093

Q38743794-0B308BFD-2723-4902-A5F6-2D5D4174AB2C

Q38743794-2F86A655-1BA4-4D9A-8411-57FB3A1C6459

Q38743794-37A63E2A-9AEE-4C09-A34E-E87524F83D6B

Q38743794-50474F2B-A126-4187-8AF9-8330121B1126

Q38743794-7D3317E8-FB23-4F8D-A714-CA12D1F51FB2

Q38743794-7FF9FC2B-AA2F-4043-8CD2-6056764B361B

Q38743794-91D143D8-D577-4F56-8560-DEBC0FC6D2F7

Q38743794-98497EE4-CF9F-456E-B318-B149CA0522B8

Q38743794-A4844CE8-1D4E-49F8-BB2C-E3F477D91191

Q38743794-C8186327-710B-48DD-AD93-5C4465382431

P2860

Q38743794-011B2244-EEA4-4504-8FD7-50FD85CE8655

Q38743794-1C3C6581-99F2-4FD4-8141-3F2AAD7360DB

Q38743794-27E87557-1829-47A9-9F1E-770FC346673C

Q38743794-32803685-834B-47FD-B7E4-D5F1DB92D68C

Q38743794-33F3E295-668D-4312-AA16-DEE4CCC27E1C

Q38743794-36912C83-FBE6-41E0-8911-F6690B2AE293

Q38743794-37653C49-1FEC-4943-9238-637DA813448D

Q38743794-42D93EC8-AA06-451C-A9EC-E44D2D13E028

Q38743794-48019968-9D73-4215-BCF2-A22B3CE5F905

Q38743794-501C4A80-C029-470C-9E90-17A42E504908

P304

Q38743794-B5122C02-E409-4437-895E-355707FC9489

P31

Q38743794-F12B3BEF-599B-4512-9415-93450C471EE6

P356

Q38743794-E8CF1E76-0FDF-4538-B818-58680D0BB1F9

P407

Q38743794-E9654C58-E07F-4BC5-A899-A53C390A6284

P433

Q38743794-8FA37DFA-A398-4C58-AF09-9E7FAF7892B0

P478

Q38743794-140893B6-610E-4A34-881C-73FE5ED280DA

P50

Q38743794-3DA93132-B4E1-4EF5-8625-365AFBF75E53

Q38743794-B6515E6D-6596-448B-B227-69D92748FD76

Q38743794-E55E89A7-4644-4E7B-9F01-B48CF2976762

P577

Q38743794-FE2DE991-DDD7-4182-B05C-A1CE21BDD082

P698

Q38743794-E1A52CAF-B5C7-40FE-993A-3A77B90C9CDC

P932

Q38743794-001C6666-EE84-4AC2-8D7E-65494B43E409

P356

J.CELL.2016.08.069

P1433

P1476

Loss of IFN-γ Pathway Genes in ...... stance to Anti-CTLA-4 Therapy.

@en

P2093

Chantale Bernatchez

http://www.w3.org/2001/XMLSchema#string

Hao Zhao

http://www.w3.org/2001/XMLSchema#string

Jennifer A Wargo

http://www.w3.org/2001/XMLSchema#string

Jianfeng Chen

http://www.w3.org/2001/XMLSchema#string

Jianjun Gao

http://www.w3.org/2001/XMLSchema#string

Lewis Zhichang Shi

http://www.w3.org/2001/XMLSchema#string

Liangwen Xiong

http://www.w3.org/2001/XMLSchema#string

Padmanee Sharma

http://www.w3.org/2001/XMLSchema#string

Patrick Hwu

http://www.w3.org/2001/XMLSchema#string

Pei-Ling Chen

http://www.w3.org/2001/XMLSchema#string

P2860

A transcriptional corepressor of Stat1 with an essential LXXLL signature motif

dbSNP: the NCBI database of genetic variation

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

The roles of IFN gamma in protection against tumor development and cancer immunoediting

The future of immune checkpoint therapy

Interferons, immunity and cancer immunoediting

The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities

ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data

P304

397-404.e9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CELL.2016.08.069

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

167

http://www.w3.org/2001/XMLSchema#string

P50

James P. Allison

P Andrew Futreal

P577

2016-09-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27667683

http://www.w3.org/2001/XMLSchema#string

P932

5088716

http://www.w3.org/2001/XMLSchema#string